Parabilis Medicines is ambitious, but it has Regeneron on its side already.
It has been a banner year for biotech buyouts, and these are two of the prime targets.
Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...
As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...
IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...
23d
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
Kardigan (KARD) didn’t just raise $400 million. The heart-drug developer sent a new signal to biotech investors about what ...
Patent cliffs are forcing Big Pharma to hunt for revenue-producing biotech assets, and three names keep surfacing in deal ...
Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...
AbbVie proved big pharma will pay up for late-stage immunology, and three names keep surfacing on Wall Street's who’s-next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results